Literature DB >> 7234660

Pharmacologic use of prostaglandin E1 in infant with congenital heart disease.

M A Heymann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7234660     DOI： 10.1016/0002-8703(81)90622-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  6 in total

1.  Cortical hyperostosis simulating osteomyelitis after short-term prostaglandin E1 infusion.

Authors:  A K Kalloghlian; H H Frayha; M M deMoor
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

Review 2.  Prostaglandins, thromboxanes and leukotrienes in clinical medicine.

Authors:  R D Zipser; G Laffi
Journal:  West J Med       Date:  1985-10

3.  Prostaglandin Availability and Association with Outcomes for Infants with Congenital Heart Disease.

Authors:  Brady S Moffett; Joshua M Garrison; Aimee Hang; Shaine A Morris; Rocky Tsang; Kimberly Dinh; Pamela Griffiths; Ronald Bronicki; Paul A Checchia
Journal:  Pediatr Cardiol       Date:  2015-10-24       Impact factor: 1.655

4.  Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease.

Authors:  B D Thanopoulos; A Andreou; C Frimas
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

5.  Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders.

Authors:  Hao Qian; Na Luo; Yuling Chi
Journal:  J Aging Res       Date:  2012-02-13

6.  Pediatric primary cardiac tumors: diagnosis and treatment.

Authors:  Avihu Z Gazit; Sanjiv K Gandhi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.